SEC Form 4 · accession 0000874015-15-000033
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph H Wender
Director
Period of report
Feb 12, 2015
Accepted (ET)
Feb 17, 2015 · 5:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 12, 2015 | M | 10,000 | $3.95 | A | 47,217 | I | By Trust |
| Common StockF2 | Feb 12, 2015 | S | 10,000 | $62.146 | D | 37,217 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Employee Director Stock Option (right to buy) | $3.95 | Feb 12, 2015 | M | 10,000 | D | Jul 1, 2009 | Jun 30, 2015 | Common Stock | 10,000 | 0 | I |
Explanation of responses
- F1Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2015.
- F2The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.960 to $62.325, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.